Hemab Therapeutics (NASDAQ:COAG) Major Shareholder Ra Capital Management, L.P. Purchases 6,387 Shares of Stock

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) major shareholder Ra Capital Management, L.P. acquired 6,387 shares of Hemab Therapeutics stock in a transaction that occurred on Tuesday, May 12th. The stock was bought at an average cost of $24.90 per share, with a total value of $159,036.30. Following the acquisition, the insider directly owned 6,372,170 shares of the company’s stock, valued at approximately $158,667,033. This trade represents a 0.10% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Monday, May 11th, Ra Capital Management, L.P. acquired 39,869 shares of Hemab Therapeutics stock. The stock was bought at an average cost of $24.81 per share, with a total value of $989,149.89.
• On Friday, May 8th, Ra Capital Management, L.P. acquired 1,483 shares of Hemab Therapeutics stock. The stock was bought at an average cost of $24.98 per share, with a total value of $37,045.34.
• On Thursday, May 7th, Ra Capital Management, L.P. purchased 9,906 shares of Hemab Therapeutics stock. The stock was acquired at an average cost of $24.46 per share, with a total value of $242,300.76.
• On Wednesday, May 6th, Ra Capital Management, L.P. purchased 68,018 shares of Hemab Therapeutics stock. The stock was acquired at an average cost of $24.60 per share, with a total value of $1,673,242.80.
• On Tuesday, May 5th, Ra Capital Management, L.P. purchased 97,411 shares of Hemab Therapeutics stock. The stock was acquired at an average cost of $24.63 per share, with a total value of $2,399,232.93.
• On Monday, May 4th, Ra Capital Management, L.P. purchased 2,675,000 shares of Hemab Therapeutics stock. The stock was acquired at an average cost of $18.00 per share, with a total value of $48,150,000.00.

Hemab Therapeutics Stock Down 0.7%

Shares of NASDAQ COAG opened at $28.37 on Friday. Hemab Therapeutics Holdings, Inc. has a twelve month low of $23.00 and a twelve month high of $36.61.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded Hemab Therapeutics to a “hold” rating in a report on Saturday, May 9th.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.